Program 2: Experimental Therapeutics

HCCC实验治疗学（ET）计划的首要目标是开发和测试新的 癌症治疗学为了实现这一目标，ET有三个中心研究主题：1）治疗靶点， 铅发现，2）新的药物输送方法和3）临床治疗。ET有30名正式成员， 17个准成员。成员在3个学院（医学，药学和文科）任命 科学）和11个部门。许多ET成员为不止一个主题做出贡献。同龄人总数 经审查的ET年度研究经费为433万美元（NCI提供244万美元），其中1044万美元用于 非同行评审的研究项目。ET成员具有很高的生产力和协作性。成员有 自2011年4月1日以来，撰写或合著了305篇癌症相关出版物，其中49%（n=148）涉及 治疗靶点和先导化合物发现，14%（n=43）涉及新的药物递送方法，36%（n=43）涉及新的药物递送方法。 （n=108）涉及临床治疗。19%（n=59）为方案内，37%（n=113）为方案间 30%（n=93）机构间。26篇论文发表在高影响力期刊上 （影响因子>10）。在治疗靶点和先导发现主题中，研究者小组合作 基于针对特定途径以及癌症类型的实验疗法。小说中 药物递送方法的主题，ET研究人员正在评估纳米颗粒，适体和新的 用于治疗前列腺癌、淋巴瘤、黑色素瘤和乳腺癌的癌症免疫疗法的方法。 临床治疗学主题的研究人员正在探索临床治疗的作用机制， 参与或领导了145项积极的临床试验，这些试验涉及一系列癌症类型， 疾病特异性多学科肿瘤组（MOG）。作为一项计划，ET越来越关注的是 促进有前途的分子靶向治疗方法的发展， 治疗管道。

The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.